Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.47 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.47 |
| ▸ | FABP7 | O15540 | 1/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 9/20 | 0.36 |
| ▸ | TYMS | P04818 | 1/20 | 0.34 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25322230 | 0.84 | PRMT5 (0.47) | PRMT5WDR77FABP7RIPK1L3MBTL1 | |
| SCHEMBL25322227 | 0.84 | PRMT5 (0.47) | PRMT5WDR77FABP7RIPK1L3MBTL1 | |
| SCHEMBL30470748 | 0.84 | PRMT5 (0.47) | PRMT5WDR77FABP7RIPK1L3MBTL1 | |
| SCHEMBL25920109 | 0.79 | FABP7 (0.41) | PRMT5WDR77FABP7RIPK1TACR1 | |
| SCHEMBL25321968 | 0.79 | FABP7 (0.41) | PRMT5WDR77FABP7RIPK1TACR1 | |
| SCHEMBL24366565 | 0.79 | PRMT5 (0.47) | PRMT5WDR77FABP7RIPK1TACR1 | |
| SCHEMBL25321972 | 0.79 | FABP7 (0.41) | PRMT5WDR77FABP7RIPK1TACR1 | |
| SCHEMBL24366032 | 0.76 | FABP7 (0.37) | FABP7RIPK1TACR1 | |
| SCHEMBL25321623 | 0.76 | PRMT5 (0.48) | PRMT5WDR77FABP7RIPK1L3MBTL1 | |
| SCHEMBL25321619 | 0.76 | PRMT5 (0.48) | PRMT5WDR77FABP7RIPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| CN-116568677-A | piperidin-1-yl-N-pyridin-3-yl-2-oxoacetamide derivatives useful for the treatment of MTAP deficiency and/or MTA accumulating cancers | 探戈医药股份有限公司 | 2023-08-08 | — | — | CN | disclosed |
| EP-4188920-A1 | PIPERIDIN-1-YL-N-PYRYDINE-3-YL-2-OXOACETAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MTA-ACCUMULATING CANCERS | Tango Therapeutics, Inc. (US) | 2023-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | PRMT5 347/4885WDR77 1263/4885FABP7 4721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.